No Clinically Significant Drug-Drug Interaction Between Scopolamine and Apixaban
Scopolamine does not have a clinically significant drug-drug interaction with apixaban (Eliquis) when taken together. Scopolamine is not a CYP3A4 or P-glycoprotein (P-gp) inhibitor/inducer, which are the primary pathways through which apixaban interacts with other medications.
Mechanism of Apixaban Drug Interactions
Apixaban's drug interactions occur through two main pathways 1, 2:
- CYP3A4 metabolism: Apixaban is partially metabolized by this hepatic enzyme
- P-glycoprotein transport: Apixaban is a substrate for this efflux transporter
Only drugs that are combined P-gp AND strong CYP3A4 inhibitors or inducers cause clinically significant interactions requiring dose adjustments 2. Examples include:
- Strong inhibitors requiring dose reduction: ketoconazole, itraconazole, ritonavir
- Strong inducers to avoid: rifampin, carbamazepine, phenytoin, St. John's wort
Why Scopolamine is Safe with Apixaban
Scopolamine is an anticholinergic agent (muscarinic receptor antagonist) that:
- Does not inhibit or induce CYP3A4 enzymes
- Does not affect P-glycoprotein transport
- Works through a completely different mechanism (acetylcholine receptor blockade) 3
While one palliative care study noted scopolamine has "high potential for drug interactions" 4, these interactions were primarily with other anticholinergic medications (causing additive anticholinergic effects like delirium) and drugs acting on histamine, acetylcholine, or dopamine receptors—not with anticoagulants.
Clinical Recommendation
No dose adjustment of apixaban is needed when co-administered with scopolamine. Continue both medications at their standard doses. The primary concern with scopolamine relates to additive anticholinergic effects with other anticholinergic drugs, not bleeding risk or anticoagulation efficacy.
Important Caveat
The main bleeding risk consideration with apixaban involves pharmacodynamic interactions with antiplatelet agents (aspirin, clopidogrel), NSAIDs, and other anticoagulants 2, 5—not pharmacokinetic interactions with scopolamine. Monitor for bleeding if the patient is on multiple medications that impair hemostasis, but scopolamine itself does not contribute to this risk.